



Revvity unveils first scientific SaaS platform to accelerate drug & materials development

12 June 2023 | News

First solution released by Revvity under the new Revvity Signals Software brand

US-based Revvity, Inc. has announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.

The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa applications into a single, robust solution that supports the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.

Developed in line with best practices for data security and integrity, the Signals Research Suite implements 24/7 global security monitoring, alerting and escalation by the Revvity Signals Software Security Operations Center. The platform can be deployed in either a multi-tenant or private-cloud environment and is designed to meet standard IT requirements for automatic updates and cloud security controls.

It is the first solution announced by the Revvity Signals Software brand since rebranding from PerkinElmer Informatics.